Home › Gastrointestinal Cancers › Minnesota › Rochester
Gastrointestinal Cancers clinical trials in Rochester, MN
4 studies for Gastrointestinal Cancers are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
- and 3 more
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Rochester
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingPhase 1/2
- Mayo Clinic, Rochester
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
RecruitingPhase 1/2
- Mayo Clinic in Rochester, Rochester
Gastrointestinal Cancers trials in other cities
- Houston, TX21 studies
- Boston, MA15 studies
- New York City, NY12 studies
- Nashville, TN10 studies
- Los Angeles, CA9 studies
- Dallas, TX8 studies
- Durham, NC8 studies
- Baltimore, MD8 studies
- Cincinnati, OH8 studies
- Arlington, VA8 studies
- San Antonio, TX7 studies
- Baldwin Park, CA7 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer37 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Colorectal Cancer29 studies
- Ovarian Cancer29 studies
- Multiple Myeloma24 studies
- Prostate Cancer22 studies
- Heart Failure22 studies
- Pancreatic Cancer22 studies
- Lung Cancer20 studies
- Endometrial Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.